Abstract: A microcapsule encapsulates a payload agent, the microcapsule having a microcapsule shell material that is rupturable (e.g., to release the encapsulated payload agent) via a retro-dimerization reaction.

Abstract: Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions.

Abstract: Provided are a fly attractant composition containing a ligninsulfonate as an active ingredient, and a fly expellant composition containing 5 to 20% by weight of a ligninsulfonate and at least 0.1% by weight but less than 5% by weight of an insecticidal active ingredient.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise various compositions, such as ECM based compositions, and structures, such as particulate structures, mesh constructs, encasement structures, coated structures and multi-sheet laminate structures.

Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.

Abstract: An intradermal delivery system comprises an immunogenic composition comprising a TLR agonist and immunogen and a microneedle. The immunogenic composition may comprise a solid biodegradable microneedle or a solid coated microneedle. The intradermal delivery system may be formulated into a skin patch.

Abstract: A nano-composition that includes nanoparticles, a method of forming the nano-composition, and a method of using the composition. The nanoparticles include a polycationic polymer ionically bonded to one or more polyanionic Glycosaminoglycans (GAGs), wherein the polycationic polymer is chitosan, methylated chitosan, poly L-Lysine, or poly L-Arginine.

Abstract: The present disclosure relates to methods and devices for controlling arthropods, including insects and arachnids in an environment. The methods generally comprise: generating a near-ideal gas Purified Hydrogen Peroxide Gas (PHPG) that is substantially non-hydrated (e.g., in the form of water in solution or water in solution or water molecules bonded by covalence, van der Waals forces, or London forces) and substantially free of e.g., ozone, plasma species, and/or organic species; and directing the gas comprising primarily PHPG into the environment such that the PHPG acts to control arachnids in the environment. In certain aspects, the arachnids may be totally or partially killed.

Abstract: Transdermal therapeutic systems that contain 4-n-butylresorcinol as an active ingredient.

Abstract: A method of delivering a health care active having the steps of administering to a mammal in need of a health benefit or a treatment for a health condition a personal health care article and consuming the article. The article contains one or more filaments that contain a backbone material, a health care active and optionally aesthetic agents, extensional aids, plasticizers, and crosslinking agents.

Abstract: The present invention discloses a process for the preparation of gadobenate dimeglumine complex in a solid form. In particular, said solid form is conveniently obtained by spray-drying a corresponding liquid suspension at a given temperature and concentration. The present invention is particularly advantageous for the industrial scale as the solid form may be obtained by employing water as a solvent, which is a non-toxic solvent, easy to handle and basically not requiring troublesome health or safety precautions.

Abstract: Described are personal care compositions comprising a polyacrylate oil gel, comprising: (a) at least one cosmetically acceptable hydrophobic ester oil, and (b) one or more polymers comprising: (i) a first polymerized unit, comprising: (1) 75% to 35% by weight, based on the weight of said polymerized unit, one or more (meth)acrylate monomers selected from at least one of C1-C4 (meth)acrylate, (meth)acrylic acid, styrene, or substituted styrene, and (2) 25% to 65% by weight, based on the weight of said polymerized unit, one or more hydrophobic monomers, including hydrophobically substituted (meth)acrylate monomers, with alkyl chain length from C6 to C22 and, (ii) a second polymerized unit, comprising: (1) 10-99% by weight, based on the weight of said polymerized unit, one or more monomers which has a Tg of more than 80° C. after polymer formation, (2) 1-10% of one or more (meth)acrylate monomers containing acid functional group, and (iii) optionally, a crosslinker.

Abstract: The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a dietary regime suitable for enhancing the effect of an anti-epileptic drug (AED) in an animal can comprise a food composition comprising a medium chain triglyceride (MCT) and the AED, wherein the MCT is present in the food composition in an effective amount for enhancing the effect of the AED when the food composition and the AED are administered to the animal.

Abstract: A topical formulation for treating human skin, having: urea; to film forming polymer; humectant; preservative; and water the above ingredients being combined such that the preservative protects the formulation against bacterial invasion, the humectant assists the formulation to retain water, and the water and film forming polymer enable the urea to be applied to human skin such that the urea sits on the skin as a stable film and is gradually absorbed into the skin to alleviate dryness or cracking.

Abstract: Disclosed is the use of a UV filter combination, comprising (a) a first UV filter selected from benzylidene malonates of formula (1), wherein R1 methyl; ethyl; propyl; or n-butyl; if R1 is methyl, then R is tert.

Abstract: A method of combating bed bugs and/or other insects in a locus containing or susceptible to presence of same, in which a DMSO-containing formulation is applied to the locus. Various pesticidal compositions are disclosed as useful for such purpose, including compositions in which DMSO is in combination with an alcohol and/or another pesticidal active agent. Compositions of the disclosure can be applied to a variety of loci, to effectively eradicate bed bugs for extended periods of time.

Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g.

Abstract: A composition of phytoglycogen nanoparticles purified from a phytoglycogen-containing plant material is provided. The composition of phytoglycogen nanoparticles is monodisperse. A method of isolating the composition from phytoglycogen-containing plant materials is provided that includes steps of microfiltration and ultrafiltration, but avoids the use of chemical, enzymatic or thermo treatments that degrade the phytoglycogen material.

Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.

Abstract: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.